Darwin AG, a European healthcare company specializing in human genetics and personalized products, has officially changed its name to Novogenia AG following the registration of the amendment to its Articles of Association in the Commercial Register. The name change, approved at the Annual General Meeting on June 26, 2026, is a strategic move to unify the company’s market presence under its core operating brand, Novogenia GmbH, which has been driving the group’s operational business and growth.
The decision to rebrand reflects the company’s focus on its wholly owned subsidiary, Novogenia GmbH, which develops and sells personalized products based on genetic analysis. The Novogenia brand is recognized for its scientific expertise and technological innovation in the field of human genetics. By adopting the Novogenia name, the company aims to simplify its corporate structure and communication, creating a consistent image across customers, business partners, investors, and the broader community.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the importance of the name change: “Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market.”
The transition from Darwin AG to Novogenia AG is part of a broader strategic process to standardize brand identity and support clearer positioning. The company stated that the name change has no impact on its strategic direction, business model, or operational activities. Shareholder rights and the stock market listing remain unchanged, with the ISIN DE000A3C35W0 continuing to apply.
Novogenia AG, headquartered in Munich, Germany, operates through the Novogenia Group, which includes subsidiaries active in human genetics and personalized product development. The company’s genetic analyses, conducted in its own laboratory, are used in disease diagnosis, treatment, and prevention, as well as in producing tailored nutritional supplements and cosmetics. Novogenia also partners with healthcare professionals such as physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize patient care based on genetic predispositions. Additionally, the group holds investments in innovative companies in the biotech, healthcare, and life sciences sectors.
For more information about Novogenia AG and its services, visit https://novogenia.com/novogenia-ag.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Darwin AG Rebrands as Novogenia AG to Unify Brand Identity and Strengthen International Position.